Double Bond Pharmaceutical AB ("Double Bond") has filed a PCT patent application to protect the use of ferrous succinate for certain indications.

Last year, a clinical study was conducted with collaboration between Double Bond  and Skellefteå University, showed that iron succinate significantly improves iron uptake, iron saturation and iron storage in patients with heart failure and iron deficiency.

Through its subsidiary Drugsson AB, Double Bond Pharmaceutical AB has the distribution rights for Inofer (iron succinate) in Sweden, Norway, Denmark and Finland.

"We are pleased with the positive clinical results of the use of ferrous succinate and strongly believe in the great market potential of the drug. Therefore, it is very important to protect the use of ferrous succinate with future patents, - comments Igor Lokot, CEO of Double Bond, - Now we will make sure to commercialize the invention in the current markets and supply the Nordic market with a very potent product ".

More about clinical study: https://mb.cision.com/Main/12720/2972792/1151388.pdf

More about Drugsson AB: www.drugsson.com 

____________________________________________________________________

Full Company Name:   Double Bond Pharmaceutical International AB (publ)

Corporate identity:       556991-6082

Stock short name:       DBP B

Share ISIN code:          SE0007185525

For more info, contact

Igor Lokot, CEO

Homepage: http://www.doublebp.com/

E-mail: info@doublebp.com

Follow us on LinkedIn and Twitter!

______________________________________________________________________________

Information about Double Bond Pharmaceutical International AB

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.